- CEO
- Yong Qun Tang
- Full Time Employees
- 1,558
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No.16 Xuefu Road,High&New Tech Development Zone Nanjing JS China 210032
- IPO Date
- Jul 19, 2017
- Business
- Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (603707.SS), founded in 1998 and headquartered in Nanjing, China, engages primarily in the research, development, production, and sales of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms, with a focus on high-end sterile injectables, heparin products, and biopharmaceuticals serving critical care, oncology, and other therapeutic areas. The company offers core products including heparin sodium APIs and finished preparations such as standard heparin, low molecular weight heparin preparations (enoxaparin sodium injections, dalteparin sodium injections, nadroparin calcium injections), oncology injectables (adalimumab injections, azacitidine, busulfan injections, bendamustine hydrochloride injections, melphalan hydrochloride injections, fluorouracil injections), critical care injectables (eptifibatide injections, carboplatin injections), and CDMO services encompassing small-molecule, macromolecule, and cellular gene therapy; it also provides over 80 USFDA-approved products through partnerships in more than 60 countries, positioning it as one of the largest suppliers of heparin APIs and high-end injectables in the US market with annual exports exceeding $250 million. Nanjing King-Friend operates manufacturing sites accredited by USFDA, EMA, PMDA, and others across injectables and APIs, targeting domestic Chinese pharmaceutical manufacturers for global expansion and international markets including the US, EU, Egypt, and Brazil. Recent developments include USFDA approval for eptifibatide injection by subsidiary Hong Kong King-Friend in May 2024; NMPA approval and USFDA submission for subsidiary Kindos' bortezomib for injection in April 2024; first-time US export of cetrorelix acetate for injection with Livzon Group in April 2024; Egyptian approval for enoxaparin sodium injection in March 2024; and an exclusive commercial licensing agreement with Meitheal Pharmaceuticals for YUSIMRY, a Humira biosimilar, announced in late 2024, alongside ongoing collaborations for overseas sales such as with Nanjing King-Friend for JZB33 regulatory applications and marketing in the US.